← Back to Clinical Trials
Recruiting NCT04375280

NCT04375280 Evaluation of Impaired Mobility in Chronic Illness Constitution of a Cohort

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04375280
Status Recruiting
Phase
Sponsor University Hospital, Clermont-Ferrand
Condition Joint Osteoarthritis
Study Type INTERVENTIONAL
Enrollment 5,000 participants
Start Date 2020-08-27
Primary Completion 2035-08-26

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Development of a screening algorithm designed to determine a "dysmobility" profile in patients with chronic illness.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 5,000 participants in total. It began in 2020-08-27 with a primary completion date of 2035-08-26.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern. Therefore, the exploration of locomotor deficiencies, physical capacities and metabolism of patients with chronic illnesses constitutes a major challenge both for the treatment of causal pathologies, as well as for evaluating the impact of therapeutic interventions, the benefit of which will be an improvement in physical capacities and ultimately mobility. In view of the hypothesis of an increase in the prevalence of mobility disorders in this population, this approach is part of a logic of screening and improving the effectiveness of the care of these patients with a multidisciplinary evaluation of individual risks. The EVALMOB protocol was designed in order to try to determine a standard profile of "dysmobility" in patients with chronic illness

Eligibility Criteria

Inclusion Criteria: * Man or woman aged 18 to 90. * Patients with chronic pathology contributing to impaired mobility. * Volunteers who have given their written consent. * Affiliated to French health care system (for France) Exclusion Criteria: * Patients suffering from progressive psychiatric pathologies (active psychosis, hallucinations, etc.) or the presence of another serious unstabilized pathology (decompensated heart failure, progressive terminal cancer, etc.). * People with poorly controlled or unstable cardiovascular disease. * Major osteoarticular or neurological problems completely preventing the proper performance of the various tests. * Non-autonomous patient * Persons under guardianship, curatorship, deprived of liberty or safeguarding justice. * People excluded from another study. * Pregnant or lactating women.

Contact & Investigator

Central Contact

Lise Laclautre

✉ promo_interne_drci@chu-clermontferrand.fr

📞 334.73.754.963

Principal Investigator

Frédéric Costes

PRINCIPAL INVESTIGATOR

University Hospital, Clermont-Ferrand

Frequently Asked Questions

Who can join the NCT04375280 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Joint Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04375280 currently recruiting?

Yes, NCT04375280 is actively recruiting participants. Contact the research team at promo_interne_drci@chu-clermontferrand.fr for enrollment information.

Where is the NCT04375280 trial being conducted?

This trial is being conducted at Clermont-Ferrand, France.

Who is sponsoring the NCT04375280 clinical trial?

NCT04375280 is sponsored by University Hospital, Clermont-Ferrand. The principal investigator is Frédéric Costes at University Hospital, Clermont-Ferrand. The trial plans to enroll 5,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology